PFE

PFE

Why shares have fallen in previous years:

COVID Product Demand Crash: A sharp decline in sales of the Comirnaty vaccine and Paxlovid led to revenues falling from $100.3B in 2022 to $58.5B in 2023.

"Patent Cliff" Concerns: The impending loss of exclusivity (LOE) for blockbusters like Eliquis, Ibrance, and Xeljanz by 2028 threatened $17–18B in annual revenue.

Weakened Guidance: Management repeatedly revised revenue and earnings forecasts downwards

Improving Fundamentals

Financial Stabilization: Pfizer finally broke the revenue instability cycle, ending 2025 with a series of "dual beats" (beating both EPS and revenue expectations).

Cost Efficiency: The management successfully implemented a multi-billion dollar cost-saving program. Margins are expanding even with moderate sales growth.

Dividend Yield ~ 6.7%

Catalysts for Future Growth

🔎